Ready to buy? Check current prices on Amazon and compare deals before you decide.
This post contains affiliate links. As an Amazon Associate we earn from qualifying purchases at no extra cost to you.
Navigating the changes that come with menopause often includes a focus on overall well-being, and cardiovascular health is a significant consideration for many women. As estrogen levels decline, the risk profile for certain cardiovascular factors can shift.
For those exploring plant-based approaches to support health during this time, red clover isoflavones and flaxseed lignans are two compounds that sometimes come up in discussions. This article will delve into what is currently understood about their potential roles in cardiovascular health during menopause, based on available information.
Understanding Cardiovascular Health in Menopause
Menopause marks a natural transition in a woman’s life, characterized by the cessation of menstrual periods and a significant decline in estrogen production. Estrogen plays a protective role in the cardiovascular system, influencing blood vessel elasticity, lipid profiles, and blood pressure regulation.
With the reduction in estrogen, women may experience changes such as alterations in cholesterol levels – most consistently a rise in total and LDL (‘bad’) cholesterol, while measured HDL (‘good’) cholesterol tends to rise even as the particles themselves grow smaller and less efficient – and shifts in blood pressure. These changes contribute to an increased focus on maintaining cardiovascular wellness during and after the menopausal transition.
Red Clover Isoflavones and Cardiovascular Support
Red clover (Trifolium pratense) is a legume rich in isoflavones, primarily genistein, daidzein, formononetin, and biochanin A. These plant compounds are phytoestrogens, meaning they have a structure similar enough to estrogen to interact with estrogen receptors in the body, albeit with a weaker effect.
Red clover’s cardiovascular research is narrower than its research on menopausal symptoms, but it is not absent. Two independent meta-analyses have pooled randomized trials of red clover isoflavones on the blood lipids of peri- and postmenopausal women, and a separate placebo-controlled crossover trial measured arterial stiffness directly. They agree on one endpoint and disagree on the rest, which is the honest starting point for anyone weighing the two options.
A 2018 meta-analysis of 12 randomized controlled trials in 1,284 peri- and postmenopausal women found red clover isoflavones significantly lowered total cholesterol (by about 12.3 mg/dL), LDL cholesterol (about 10.6 mg/dL) and triglycerides (about 10.2 mg/dL), with a small increase in HDL[1]. A 2020 meta-analysis of a specific standardized extract, covering 10 studies in 910 women, reproduced the total-cholesterol reduction (about 11.2 mg/dL, p = 0.014) but found the LDL, triglyceride and HDL changes were not statistically significant, with very high variability between trials[2]. Taken together, the total-cholesterol effect is the most reproducible finding and the rest depends heavily on which trials are pooled.
Vascular function has been measured directly as well. In a randomized, double-blind crossover trial, 80 adults aged 45 to 75 (including 34 postmenopausal women) took 80 mg/day of red clover isoflavones for six weeks. Arterial stiffness improved significantly (systemic arterial compliance p = 0.04, central pulse wave velocity p = 0.02) and total peripheral resistance fell (p = 0.03), while blood pressure (p = 0.5) and flow-mediated dilation (p = 0.44) did not change[3]. The authors noted the benefit appeared to come from the formononetin-enriched preparation rather than isoflavones generally, though that subgroup comparison was itself borderline (adjusted p = 0.06). It is one trial, and it was not menopause-specific.
Flaxseed Lignans and Cardiovascular Support
Flaxseed (Linum usitatissimum) is another plant-based source of phytoestrogens, specifically lignans, with secoisolariciresinol diglucoside (SDG) being the primary lignan. Like isoflavones, lignans are metabolized in the gut into compounds that can weakly bind to estrogen receptors.
Here the comparison needs to be more specific than most write-ups allow, because whole ground flaxseed, an isolated lignan supplement and flaxseed oil are three different interventions, and the trials keep them separate because they do not produce the same results.
A meta-analysis of 28 randomized trials found flaxseed lowered total and LDL cholesterol, with the significant reductions coming from whole flaxseed and from lignan supplements but not from flaxseed oil, and the effect was most apparent in women, particularly postmenopausal women[4]. A three-month randomized trial in postmenopausal women taking 40 g/day of ground flaxseed lowered total and non-HDL cholesterol by about 6%, along with apolipoprotein A-1 and apolipoprotein B (both p < 0.005)[5].
The counter-example matters just as much. A randomized crossover trial gave healthy postmenopausal women an isolated lignan complex supplying 500 mg/day of SDG for six weeks. It raised circulating enterolactone exactly as intended, and still changed nothing: not total, LDL or HDL cholesterol, not triglycerides, not antioxidant capacity[6]. Delivering the lignan is not the same as producing the effect.
On blood pressure the flaxseed evidence is stronger than on lipids. Pooling 33 trials in 2,427 participants, flaxseed supplementation lowered systolic pressure by about 3.2 mmHg and diastolic pressure by about 2.6 mmHg (both p < 0.001), with larger effects in trials running beyond 20 weeks, at doses of 30 g/day or more, and in people who were overweight or already hypertensive[7].
Comparing Red Clover Isoflavones and Flaxseed Lignans
When comparing red clover isoflavones and flaxseed lignans for cardiovascular health during menopause, it’s important to recognize that both are phytoestrogens and have been explored for similar potential benefits. However, their chemical structures and metabolic pathways differ, leading to potentially distinct interactions within the body.
So the useful comparison is not “both unproven”. The two have been tested on different endpoints, in different populations, at different doses. Red clover’s lipid evidence sits squarely in the peri- and postmenopausal population this article is about, and its most reproducible effect is on total cholesterol. Flaxseed’s strongest evidence is on blood pressure, but it comes from trials of the ground seed at food-sized doses rather than from a capsule. For lignan supplements specifically the picture is genuinely mixed: pooled across trials they lowered cholesterol, while the one dedicated trial in healthy postmenopausal women moved nothing.
That makes the choice less arbitrary than preference and availability. If the target is cholesterol during the menopausal transition, red clover has been tested in that exact population. If the target is blood pressure, the flaxseed evidence is larger but asks for a food-sized daily portion of ground seed, not a lignan capsule, and it was gathered largely in people who were overweight or hypertensive to begin with.
What the Current Evidence Suggests
One absence claim in this area is real, and it is worth stating plainly: neither red clover isoflavones nor flaxseed has been shown to reduce actual cardiovascular events such as heart attack or stroke. Everything above is a change in a risk marker (cholesterol, blood pressure, arterial stiffness) measured over weeks to months, and a marker moving is not the same thing as an outcome changing.
In practice that makes both supporting measures alongside the things that do have outcome evidence, not replacements for them. The effect sizes are modest, the two red clover lipid meta-analyses disagree on everything except total cholesterol, and the flaxseed blood pressure data comes disproportionately from people who were already at elevated risk. Anyone managing a diagnosed cardiovascular risk factor should treat either one as an addition to medical care rather than an alternative to it.
References
- Effects of red clover on perimenopausal and postmenopausal women's blood lipid profile: A meta-analysis. Climacteric : the journal of the International Menopause Society, 2018
- Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of perimenopausal and postmenopausal women-A systematic review and meta-analysis. Maturitas, 2020
- Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. Arteriosclerosis, thrombosis, and vascular biology, 2003
- Meta-analysis of the effects of flaxseed interventions on blood lipids. The American journal of clinical nutrition, 2009
- Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. The Journal of clinical endocrinology and metabolism, 2002
- A lignan complex isolated from flaxseed does not affect plasma lipid concentrations or antioxidant capacity in healthy postmenopausal women. The Journal of nutrition, 2006
- Effect of flaxseed supplementation on blood pressure: a systematic review, and dose-response meta-analysis of randomized clinical trials. Food & function, 2023
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
